STEMCELL-TECHNOLOGIES
18.8.2021 12:02:03 CEST | Business Wire | Press release
STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use of tissue-derived organoids—including lung, intestinal, and liver organoids—for use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. These services will help researchers and organizations working on drug development incorporate organoids into their preclinical testing programs and bring new therapeutics to market faster and more cost-effectively.
HUB Organoids™ are experimental models derived from the adult stem cells present in epithelial tissues. Expansion and differentiation of these stem cells gives rise to functional “mini-organs in a dish”. HUB Organoids™ represent a patient-specific way of assessing the efficacy and toxicity of drugs during preclinical screening. By closely mimicking human biology, HUB Organoids™ can be used to more accurately predict patient response to treatment than traditionally used systems. As such, they have the potential to drastically lower the costs and failure rates currently associated with bringing new treatments to market. Under the existing agreement, STEMCELL develops and supplies a wide range of cell culture kits that efficiently expand and maintain the different stem cell-derived organoids that will be used for many of these screening programs.
This new agreement complements HUB and STEMCELL’s existing partnership, where STEMCELL is the exclusive provider of cell culture media for all HUB Organoids™, by allowing STEMCELL to perform preclinical toxicology screening as well as non-cancer drug testing and validation services. "We are extremely pleased to be able to expand our partnership with HUB to include these new services," remarked Dr. Allen Eaves, STEMCELL’s Founder, President, and CEO. "As Scientists Helping Scientists, our goal is to make these incredible technologies more accessible to researchers, whether they are growing organoids in their own labs or partnering with service providers to advance their science."
“At HUB we are on a mission to bridge the gap between the lab and the clinic and bring patients-specific models into the lab,” said Dr. Robert Vries, HUB CEO. “Carefully selecting our strategic partners is key to expanding global access to HUB Organoid Technology and, ultimately, to improving patient care. STEMCELL has already demonstrated thought leadership in the Organoid Technology field; therefore, we believe that expanding the scope of our partnership to include services will benefit the research and drug development community worldwide.”
About STEMCELL Technologies
As Scientists Helping Scientists, STEMCELL Technologies is committed to providing high-quality cell culture media, cell isolation products, accessory reagents and services for life science research. Driven by science and a passion for quality, STEMCELL Technologies offers over 2500 products designed to support the basic to translational research continuum. Visit www.stemcell.com to learn more.
About HUB
Hubrecht Organoid Technology (HUB) was founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and Sciences (KNAW) to refine organoid development and foster organoid adoption globally. HUB Organoid Technology represents a paradigm-shift that bridges the gap between the lab and the clinic and effectively brings “patients in the lab” for drug discovery and development, preclinical patient stratification, predictive biomarker discovery, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics applications. Learn more by visiting www.huborganoids.nl
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005144/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom